Vaxcyte (PCVX, 4.3% weighting in the Portfolio) is a leader in novel vaccine chemistry, which has enabled it to create a broad coverage pneumococcal vaccine (PCV) that is unlikely to be matched by ...

Imaging wall-less plant cells every six minutes for 24 hours revealed how the cells build their protective barriers.

From a tiny sample of tissue no larger than a grain of sand, scientists have come within reach of a goal once thought unattainable: building a complete functional wiring diagram of a portion of the ...

Plant cells without walls, known as protoplasts, are very fragile, and it has been difficult to keep them alive under a ...

Researchers are studying why the energy factories are moving between cells and whether the process can be harnessed to treat ...

Scientists have attempted to map the human cell since the first microscope was invented more than 400 years ago. But many ...

In an attempt to strike a pitch-perfect tone with Generation X, Pfizer has recruited Elizabeth Banks as the face of a new awareness campaign for pneumococcal pneumonia vaccination. Toward the end ...

In a growing global trend, bacteria are evolving new ways to maneuver around medical treatments for a variety of infections.

Apr. 11, 2025 — A multi-institutional team developed a chimeric antigen receptor (CAR) T cell-based strategy for specifically targeting AML cells in patients who relapsed following other treatments.

Vaxcyte's new pneumococcal vaccine may only have phase ... becoming the first approved oral therapy for giant cell arteritis.

The fall in PCVX shares was further amplified by mixed results from a mid-stage study on its pneumococcal vaccine ... and shaping regulatory pathways for cell and gene therapies, his exit raises ...